Specialty Pharmacy

Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.

Bodily fluids may serve as vectors for transmission for transmitting hepatitis C virus RNA in patients with a high viral load.

Evolocumab (Repatha) consistently reduced low-density lipoprotein cholesterol in high-risk patients over time.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

Each year, the Institute for Safe Medication Practices (ISMP) releases its review of the year's most common medication safety issues.

With the increasing use of these treatments in the oncology space, pharmacists should be knowledgeable about how to best manage patients on immunotherapy.

Getting involved in advocacy efforts is key to showing the value of the pharmacy profession.

Specialty pharmacies offer a wide range of services vital to manufacturers and patients alike.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

What if there was a drug delivery system intuitive enough to respond to changes in a patient’s disease?

Cheyenne Newsome, PharmD, PhC, BCACP, clinical assistant professor at the Washington State University College of Pharmacy, discusses the health disparities seen in the LGBTQ community and what considerations providers should keep in mind when treating transgender patients.

HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.

The annual forecast predicts developments in different areas that are likely to challenge pharmacy practice leaders in hospitals and health systems in the future.

Michael Ganio, PharmD, MS, BCPS, FASHP, ASHP Director of Pharmacy Practice and Quality, talks about biosimilar use and factors influencing uptake in the United States.

An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

As biosimilar development continues to grow, pharmacists will be essential in transitioning both clinicians and patients alike in the use of these therapies.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Christopher Topoleski, who is the Director of Federal Legislative Affairs for ASHP, discusses the ongoing legislative efforts targeting drug prices and what to expect moving forward.

Mark Eastham, BS, RPh, Senior Vice President of McKesson RxO, discusses the growth of specialty pharmacy in the health system space.

Phase 2 data show positive results for a therapy including 2 immune checkpoint inhibitors and chemotherapy.

Top news of the day from across the health care landscape.

Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.

At the 2018 ASHP Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, offered advice on how pharmacy providers can work to overcome biosimilar reimbursement challenges and encourage biosimilar adoption.